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The translocation t(11;14)(q13;q32) is the genetic hallmark of mantle cell lymphoma (MCL) but is not sufficient for 
inducing lymphomagenesis. Here we performed genome-wide 100K GeneChip Mapping in 26 t(11;14)-positive 
MCL and 6 MCL cell lines. We show that partial uniparental disomy (pUPD) is a recurrent chromosomal event not 
only in MCL cell lines but also in primary MCL. Remarkably, pUPD affects recurrent targets of deletion like 11q, 
13q and 17p. Moreover, we identified 12 novel regions of recurrent gain and loss as well as 12 high-level 
amplifications and 8 homozygously deleted regions hitherto undescribed in MCL. Interestingly, GeneChip 
analyses identified different genes, encoding proteins involved in microtubule dynamics, such as MAP2, MAP6 
and TP53, as targets for chromosomal aberration in MCL. Further investigation, including mutation analyses, 
fluorescence in situ hybridisation as well as epigenetic and expression studies, revealed additional aberrations 
frequently affecting these genes. In total, 19 of 20 MCL cases, which were subjected to genetic and epigenetic 
analyses, and 5 of 6 MCL cell lines harboured at least one aberration in MAP2, MAP6 or TP53. These findings 
provide evidence that alterations of microtubule dynamics might be one of the critical events in MCL 




Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (B-NHL) genetically characterised 
by the translocation t(11;14)(q13;q32) that leads to overexpression of cyclin D1 (Williams, et al 1992). Based on 
studies with transgenic mice, it is well established that this chromosomal event alone is not sufficient to result in 
lymphomagenesis and that secondary genomic alterations are required for malignant transformation (Gladden, et 
al 2006, Lovec, et al 1994). In this multistep transformation process, tumour suppressor gene (TSG) inactivation 
has been shown to be a key mechanism. In MCL, frequently targeted TSGs encode for proteins that inhibit 
malignant transformation by protecting the genome from DNA damage (ATM) or from deregulated cell cycle 
progression (CDKN2A/P16, RB1) or by inducing apoptosis in cells with a disrupted cell cycle control 
(TP53)(Nielander, et al 2007).  
MCL has been the subject of several array-based comparative genomic hybridisation (arrayCGH) studies, and 
genomic aberrations in addition to t(11;14)(q13;q32) have been extensively characterised (de Leeuw, et al 2004, 
Kohlhammer, et al 2004, Mestre-Escorihuela, et al 2007, Rubio-Moscardo, et al 2005a, Rubio-Moscardo, et al 
2005b, Tagawa, et al 2005). Except one, all these studies used microarrays consisting of bacterial artificial 
chromosome (BAC) or P1-artificial chromosome (PAC) clones for which maximal resolution is restricted to 50-200 
Kb. Microarrays consisting of short synthetic oligonucleotides provide higher resolution. Some platforms allow 
genotyping simultaneously, so that loss of heterozygosity (LOH) without changes in DNA copy number is also 
detectable. This chromosomal event, so called partial uniparental disomy (pUPD), has been recently reported as 
a frequent mechanism of TSG inactivation in haematological neoplasms and solid tumours (Bignell, et al 2004, 
Bruce, et al 2005). In 2006, we could show that pUPD is a recurrent genetic mechanism alternative to 
chromosomal deletion in MCL cell lines (Nielaender, et al 2006). By loss of (part of) one parental chromosome 
and duplication of the remaining one from the other parent, pUPD results in LOH without chromosomal deletion. 
As the gene dosage is not altered, pUPD cannot be detected by conventional arrayCGH.  
In the present study, we used 100K GeneChip arrays to determine genomic imbalances and pUPD in a series of 
26 mantle cell lymphoma and 6 MCL cell lines. Taking advantage of the high resolution of this array, we focused 
on detection of small homozygous deletions. Moreover, this microarray enables to identify pUPD. The detection of 
these two genetic alterations has been shown to be a promising strategy to identify novel TSGs (Nielander, et al 
2007). We identified minimally altered regions targeted by homozygous deletions harbouring novel candidate 
TSG loci, which might be associated with MCL pathogenesis. Moreover, we could show that pUPD is a recurrent 
chromosomal event not only in MCL cell lines, but also in MCL primary cases and leads to inactivation of TSGs. 
This further confirms that pUPD has to be considered as an alternative mechanism of TSG inactivation in MCL. 
Finally, our study identified genes encoding microtubule-associated proteins to be frequently targeted by 
chromosomal and epigenetic aberrations in MCL. 
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Methods and Materials 
Tissue samples. DNA-samples and fixed cells were selected from the files of the Institute of Human 
Genetics, the Second Medical Department and the Institute of Haematopathology, (University Hospital Schleswig-
Holstein, Campus, Kiel, Germany). Genomic DNA was extracted from frozen DMSO stocks derived from lymph 
node (LN), peripheral blood (PB), bone marrow (BM) and spleen (S) or from frozen tissue blocks of the affected 
LN using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). The MCL panel for SNP array comprises 
26 primary MCL. The median age of the patients at diagnosis was 66 years (range from 38 to 84 years). A subset 
of cases of this panel were also used for fluorescence in situ hybridisation (FISH) (n=13), MAP2 mutation 
analyses (n=20), TP53 mutation analyses (n=26) and epigenetic studies (n=20). For the FISH screenings and 
denaturing high performance liquid chromatography (DHPLC) analyses of the MAP2 gene, additional 14 and 20 
t(11;14)-positive MCL cases from files of the Institute of Human Genetics (University Hospital Schleswig-Holstein, 
Campus, Kiel, Germany) were included, respectively. Supplementary Table 1 shows all MCL samples included in 
this study. Tonsils and PB of healthy donors were used as non-tumourous controls. For real time RT-PCR 
experiments, LN cDNA pooled from 12 Caucasians (ages 20-59) and purchased from the human immune system 
multiple tissue cDNA panel (Clontech Laboratories, Mountain View, CA) and a tonsil freshly prepared from the 
Institute of Haematopathology (University Hospital Schleswig-Holstein, Campus, Kiel, Germany) were used as 
normal controls. The study was performed in the framework of the “European MCL Network”, for which central 
and local ethics approval was obtained. 
Cell lines. A panel of 6 MCL cell lines was studied: GRANTA-519, HBL-2, UPN-1, REC-1, MAVER-1 and 
JEKO-1. A compilation of studies characterising these cell lines is shown in Supplementary Table 2. 
Microarrays. The GeneChip Human Mapping 100K array set (Affymetrix, Santa Clara, CA, USA) has been 
used according to the protocol provided by the manufacturer (Affymetrix, Santa Clara, CA) 
(http://www.affymetrix.com). Microarrays were washed and stained with the Fluidics Station 450 (Affymetrix, 
Santa Clara, CA) and scanned with the GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA) using GeneChip 
Operating System (GCOS; Affymetrix, Santa Clara, CA) version 1.4. The BRLMM algorithm (2006) was used with 
default parameters (score threshold=0.5, prior size=10000 and DM threshold=0.17) to genotype MCL tumour 
samples in combination with Hapmap reference arrays (2006). The genotyping call rates of the hybridised SNP 
chips ranged from 96.06% to 99.88% (median = 98.59%) for the 50K XbaI array and from 94.54% to 99.77% 
(median = 98.92%) for the 50K HindIII array. Ninety HapMap samples provided by Affymetrix (30 CEPH trios) 
were used as normal reference arrays (http://www.affymetrix.com/support/technical/sample_data/ 
hapmap_trio_data.affx). A complete list of Affymetrix reference samples is shown in Supplementary Table 3. 
Copy Number Analysis. Copy number analysis was performed using the CNAG program v2.0 (Nannya, et al 
2005). The optimised reference selection method implemented in CNAG was used (Nannya, et al 2005). Thus 
CNAG selected a gender-specific reference set out of the 90 controls individually for each array. XbaI and HindIII 
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arrays were combined for the analysis. Segmentation of raw copy number data was performed using the Hidden 
Markov Model (HMM) approach provided by CNAG. HMM parameters were adjusted individually for each array 
due to differences in hybridisation quality and tumour cell content. Starting with default parameters, the mean 
levels of HMM states were adjusted manually to increase smoothing for samples with higher noise while 
increasing sensitivity for low noise samples. With regard to outliers and technical artefacts, HMM segments with 
aberrant copy number were considered as copy number aberration only if they consisted of at least 10 
consecutive SNPs. High level amplifications were defined as aberrations with HMM copy number  5.  For male 
cases, the call of high level amplifications on chromosome X was copy numbers  4. 
Liberal screening for homozygous deletions. Homozygous deletions were defined as aberrations with copy 
number = 0.  
Sensitive screening for homozygous deletions. In this more sensitive approach for detecting homozygous 
deletions, the Copy Number Analysis Tool (CNAT; Affymetrix, Santa Clara, CA, USA) version 2.0 was used to 
calculate the copy number (CN), applying a 0.5Mb genome smoothing filter. The data set was screened for 
regions with a copy number  0.6 in a minimum of two adjacent SNPs of which at least one showed a “NoCall”. 
LOH analysis. A HMM based method (Beroukhim, et al 2006) implemented in the dChip program (Lin, et al 
2004, Zhao, et al 2004) (Build date: Apr 11 2007) was used to infer regions with LOH from tumour samples. The 
HMM considering haplotype (LD-HMM) (Beroukhim, et al 2006) method was selected for the LOH calculations to 
account for linkage disequilibrium (LD)-induced SNP dependencies. The LOH call threshold was set to the default 
value of 0.5. An empirical haplotype correction (Beroukhim, et al 2006) was applied. Thus, the genotypes of 
putative tumour-associated LOH regions were compared with the genotypes observed in euploid reference 
samples. If the genotypes in the respective region were highly concordant between the tumour sample and at 
least 5% of the normal reference samples the LOH region was rejected by dChip. 
Partial uniparental disomy. Partial UPD regions represent genomic regions in which the LOH is not caused 
by altered copy number. A LOH region determined by dChip was called UPD if the copy number analysis using 
CNAG revealed no aberrations within that region. If a LOH region was partially affected by copy number 
aberrations, subregions with normal copy number were called UPD if they comprised at least 50 neighbouring 
SNPs.  
Copy number polymorphisms. As an attempt to distinguish copy number aberrations from copy number 
variations (CNVs) present in healthy individuals, aberrant regions were compared to published data included in 
the “Database of Genomic Variants” (http://projects.tcag.ca/variation/). Regions showing overlap ≥50% with 
known genomic variants were classified as CNVs. 
Interphase FISH. The commercially available locus-specific identifier (LSI) IGH/CCND1 dual colour probe 
(Abbott/Vysis, Downers Grove, IL) was applied to detect translocation t(11;14)(q13;q32). Differentially labeled 
bacterial artificial chromosome (BAC) clones, fosmid clones or commercial centromere probes (Abbott/Vysis) 
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were applied to verify copy number results from 100K GeneChip analyses and to perform FISH screenings. A 
summary of the used FISH assays is shown in Supplementary Table 4. FISH was performed as published 
elsewhere (Martin-Subero, et al 2002). 100 nuclei were evaluated per hybridisation whenever possible. 
Delineation of homozygous deletions. Polymerase chain reaction (PCR)-based methods were used to 
confirm homozygous deletions detected in the SNP array data of the MCL cell lines. To identify novel candidate 
TSGs, regions of homozygous loss were delineated by PCR. Primer sequences, polymerase enzymes and PCR 
conditions are summarised in Supplementary Table 5. 
Mutation analyses. The coding exons and exon/intron-boundaries of MAP2 were amplified and analysed by 
DHPLC as previously described (Arnold, et al 1999). Sequences and annealing temperatures of primer pairs are 
shown in Supplementary Table 5. PCR products which showed aberrant chromatograms were subjected to direct 
sequencing using the Big Dye Terminator v1.1 Cycle Sequencing Kit and the Genetic Analyser ABI PRISM 310 
system (Applied Biosystems, Foster City, CA). TP53 mutation analysis was performed as previously described 
(Gross, et al 2001). Sequence variations were checked and named according to the R12 release of the IARC 
TP53 Database (Petitjean, et al 2007) to determine whether they are rare polymorphisms or deleterious.  
Methylation studies. Sodium bisulfite conversion of genomic DNA was performed with EpiTect Bisulfite Kit 
(Qiagen, Hilden, Germany). The methylation status of MAP2 was evaluated by methylation-specific PCR (MSP) 
(Herman, et al 1996) as well as bisulfite sequencing (Frommer, et al 1992). For bisulfite sequencing, the whole 
CpG island upstream of the MAP2 gene was amplified after DNA bisulfite treatment, ligated into a pCR2.1-TOPO 
vector and transformed into competent E.coli (TOP10) using the TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA). 
Insertion of the DNA fragments was tested by PCR of the colonies. Cloned DNA was amplified from 10 positive 
colonies using vector-specific primers followed by direct sequencing using Big Dye Terminator v1.1 Cycle 
Sequencing Kit and the Genetic Analyser ABI PRISM 310 system (Applied Biosystems, Foster City, CA). Primer 
sequences for MSP and bisulfite sequencing, the used polymerase enzymes and PCR conditions used in the 
analyses are shown in Supplementary Table 5. To control the result of bisulfite conversion and the specificity of 
the MSP reactions, we used CpGenome Universal Methylated and CpGenome Universal Unmethylated DNA 
(Millipore, Billerica, MA).   
Expression studies. MAP2 and MAP6 expression in MCL cell lines was analysed by SYBR Green based 
real-time RT-PCR using the iCycler iQ multi-color-real-time PCR detection system (Biorad, Hercules, CA). Total 
RNA was isolated from cultured cells with NucleoSpin RNA/Protein Kit (Macherey-Nagel, Düren, Germany), high 
quality was confirmed with the Experion automated electrophoresis system (Biorad, Hercules, CA) and cDNA 
synthesis was performed using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany). For the real-
time PCR of MAP2 we used QuantiTect SYBR Green PCR Kit and the QuantiTect Primer Assays of MAP2 (Hs_ 
MAP2_1_SG) and MAP2 alternative transcripts (Hs_MAP2_va.1_SG) (Qiagen). These two primer assays are 
able to detect all known transcript variants of MAP2. For MAP6 real time PCR we used the QuantiTect Primer 
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Assay Hs_ MAP6_1_SG. Normalisation for the quantity of cDNA was done by performing simultaneous real-time 
RT-PCR for hypoxanthine phosphoribosyltranferase 1 (HPRT1), -glucuronidase (GUSB) and glucose-6-
phosphat-dehydrogenase (G6PD) with appropriate QuantiTect Primer Assays (Hs_HPRT1_1_SG, 
Hs_GUSB_1_SG, and Hs_G6PD_1_SG) (Qiagen). The thermal profile for the SYBR Green-based PCRs 
consisted of 15min Taq polymerase activation at 95°C followed by 45 cycles of PCR at 94°C for 15s 
(denaturation), 55°C for 30s (annealing), and 72°C for 30s (extension). Following amplification, a melting curve 
analysis was performed to verify the correct product by its specific melting temperature (Tm). Melting curve 
analysis consisted of a denaturation step at 95°C for 1min, lowered to 55°C for 30s, and followed by 80 cycles of 
incubation in which the temperature is increased to 95°C at a rate of 0.5°C/10s/cycle with continuous reading of 
fluorescence. Results were analysed by iCycler iQ Optical Software Version 3.0a and ratios were calculated by 
CT method. 
Results 
GeneChip array data  
In this study, 26 MCL from 20 male and 6 female patients have been subjected to 100K GeneChip Mapping 
analyses. The characteristic translocation t(11;14)(q13;q32) was confirmed by cytogenetics and/or FISH. Based 
on FISH, the tumour cell content varied from 21% to 95% (mean 75%) (Supplementary Table 1). In addition, a 
panel of six t(11;14)-positive MCL-derived cell lines was studied. Results of the LOH analysis based on this 100K 
GeneChip array data have already been published for 5 of these MCL cell lines (Nielaender, et al 2006). 
Gains and losses. Copy number analyses identified a pattern of genomic imbalances typical for MCL, 
including low-level gain and monoallelic loss of regions which are known to be recurrently affected in MCL. A 
genomic overview of gains and losses detected in the investigated MCL primary cases is given in Figure 1. 236 
and 204 genetic events leading to monoallelic loss were identified in the primary MCL and MCL cell lines, 
respectively (mean of 9 per MCL and 34 per MCL cell line). In addition to deletions, 206 low-level copy gains were 
detected in the primary MCLs (mean of 8 per MCL) and 181 in the MCL cell lines (mean of 30 per MCL cell line). 
By overlapping genomic segments showing copy number changes, we delineated the minimal altered regions 
(MARs) as well as minimal peak regions within these MARs, which were determined by imbalances of single 
cases (Supplementary Figure 1). Chromosomal regions which were affected in at least 4 primary MCL or MCL 
cell lines are summarised in Supplementary Table 6. Frequently affected regions of chromosomal gain were 
identified in 1q23.3-q25.1, 2p25.1, 2q32.3, 3q27.3-3q28, 4q35.1-q35.2, 7p22.3-p15.3, 7p12.1, 7q21.11, 8p23.3, 
8q22.1-q24.21, 10p15.3, 10p12.1-p11.22, 11q13.3-q21, 12q13.3-q14.1, 13q31.3, 14q11.2, 15q21.3, 17q23.2, 
18q21.2-q22.3 and 19p12. Genomic loss was frequently detected in 1p33-p32.3, 1p31.1-p21.1, 2q13, 2q24.1-
q31.2, 2q37.1, 3p14.2-p12.2, 6q23.3-q27, 8p23.2-p21.2, 9p24.3-p21.2, 9q13-q31.2, 10p14-p13, 11q22.3-q23.2, 
12p13.2-p13.1, 13q12.3-q13.1, 13q14.2-q14.3, 13q22.2-q31.1, 13q34, 14q32.12, 15q11.2, 17p13.3-p12, 
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22q11.22, 22q13.2-q13.33, and Xp22.33. Some of these regions contain known CNVs, also present in healthy 
individuals. These CNVs are marked in Supplementary Table 6. In addition to common alterations previously 
reported in MCL, 100K GeneChip mapping identified 5 regions frequently targeted by chromosomal gain as well 
as 7 regions of recurrent genomic loss, which have not been reported yet. Some of these novel regions contain 
candidate genes showing typical tumour suppressor or oncogene properties such as FHIT in 3p13, CDKN1B in 
12p13.1, MYCBP in 13q22.3, or CDKN2AIP and ING2 in 4q35.1 (Supplementary Table 6). 
High-level amplifications. Regions showing a copy number  5 were classified as high-level amplified. 
Amplicons included genes previously described as being amplified or overexpressed in MCL like BCL2 
(18q21.33), GPC5/miR-17-92 (13q31.3) and BMI1 (10p12.2) (Bea, et al 2001, de Leeuw, et al 2004, Rubio-
Moscardo, et al 2005b). Novel detected regions of genomic amplification in MCL involved chromosomes 4p14, 
6p21.2, 8p23.1, 8p23.1-p22, 8q24.21, 11q13.4-q13.5, 11q14.1, 11q22.3, 11q23.1-q23.2, 17p11.2, 18q12.2 and 
18q12.2-q12.3 (Supplementary Table 7). Noteworthy, most of the detected high-level amplifications (~90%) were 
observed in the MCL cell lines. There were only 2 primary MCL cases showing this kind of aberration. Each of 
these newly detected amplified regions was observed in only one sample with the exception of 11q13.4-q13.5, 
which was detected in 3 MCL cell lines. This region harbours 9 genes including MAP6 (microtubule-associated 
protein 6), SERPINH1 (serine proteinase inhibitor 1), GDPD5 (glycerophosphodiester phosphodiesterase domain 
5), RPS3 (ribosomal Protein S3), UVRAG (UV radiation resistance associated gene), WNT11 (wingless-type 
MMTV integration site family), MOGAT2 and DGAT2 (mono- and diacylglycerol O-acyltransferases), as well as 
the hypothetical protein LOC283212. In addition, this chromosomal region is coding for 2 snoRNAs (U15A and 
U15B).  
Homozygous deletions. Two different approaches were used for the identification of candidate 
homozygously deleted regions in the MCL GeneChip data. In the liberal screening of the MCL cell lines, 11 
homozygous deletions were identified in 8 different chromosomal regions and except the CNV all of them were 
proven by PCR and/or FISH (Table 1). Applying the sensitive screening method, 19 additional candidate 
homozygous deletions all affecting different loci were identified in MCL cell lines. Four of them could be validated 
by PCR and/or FISH, two were consistent with known CNVs (Table 1). The additional 13 regions suggestive for 
homozygous loss could not be confirmed. Noteworthy, this evaluation criteria detected every previously reported 
homozygous deletion in MCL cell lines, including TSG loci in 1p32.3 (INK4C/P18), 2q13 (BIM), 9p21.3 
(INK4C/P16), and 13q14.2 (RB1) (Nielander, et al 2007). Nevertheless, 43% of the regions suggestive for 
homozygous deletion represented false positive findings. However, four PCR-proven homozygously deleted 
regions and two CNVs detected by the sensitive screening were not detected by the liberal approach, most likely 
due to smoothing of the data. Table 1 displays the verified regions of homozygous loss in the MCL cell lines 
detected by both approaches. Moreover, the borders of 5 novel deleted regions were delineated by PCR to 
identify potential TSGs (Table 1). 
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In the 26 primary MCL cases 15 and 6 regions met the criteria for homozygous deletion in the sensitive and 
liberal approach, respectively. Confirmation by PCR-based methods was not performed due to contamination of 
the tumour samples by normal surrounding tissue. FISH was only applied for verification of deletions exceeding 
~100 kb (i.e. the insert size of the used BAC, PAC or fosmid clones) which were not classified as CNVs. 
Homozygous deletion could be confirmed in 9p21.3 and in Xp22.33. In Table 2, regions of homozygous loss, 
which were detected by GeneChip data analysis of the MCL primary cases, are summarised with regard to size, 
CNVs, target genes and FISH verification. 
Loss of heterozygosity in regions with normal copy number. 100K GeneChip data of the primary MCL 
cases was also subjected to LOH analyses in order to identify regions of pUPD. A median number of 1.6 pUPDs 
(ranging from 0 to 5) was identified in the samples. As previously reported for MCL cell lines (Nielaender, et al 
2006), regions frequently affected by pUPD in  primary MCL are known to be commonly targeted by deletions in 
MCL, e.g. 11q and 13q (Figure 2A). Some of the detected regions showing pUPD are known to harbour common 
TSGs, like TP53 in 17p13.1.  
Mutation analyses of TP53 in one MCL sample displaying pUPD in the short arm of chromosome 17 (Figure 
2B) revealed a homozygous missense mutation of a single nucleotide (g.14490 T>A) in exon 8, affecting a DNA 
binding domain (Figure 2C). This mutation has been reported to be deleterious for TP53-DNA interaction 
(http://www-p53.iarc.fr). FISH analysis using a TP53 locus-specific probe confirmed a normal gene dosage of two 
copies (Figure 2D).      
Involvement of genes encoding microtubule-associated proteins in MCL 
Remarkably, 100K GeneChip data and further investigation of candidate genes identified genes encoding 
different microtubule-associated proteins such as MAP2, MAP6 and TP53 to be recurrently affected by 
chromosomal aberrations in MCL. Although it is widely known that MCL karyotypes show high complexity, 
alterations in microtubule organisation have not been reported so far.  
MAP6 gene. High-level amplification of the MAP6 gene was confirmed in all 3 MCL cell lines MAVER-1, 
JEKO-1 and HBL-2 by FISH using a BAC clone spanning the MAP6 locus. A combined analysis of FISH and R-
banding revealed the existence of 2 derivative chromosomes 6 harbouring the amplified 11q13.5 region in 
MAVER-1 (Figure 3). A FISH screening on interphase nuclei of 27 primary MCL identified one case with 5 gene 
copies, although the control gene locus in 11q22.3 was also involved. To investigate if gene dosage affects MAP6 
expression, we performed real-time RT-PCR in the 6 MCL cell lines. Higher expression of MAP6 was detected in 
JEKO-1, GRANTA-519 and REC-1 compared to a freshly prepared tonsil, which was used as normal control 
(Supplementary Figure 2). 
MAP2 gene. Homozygous deletion of MAP2 detected in the MCL cell line UPN-1 was confirmed by PCR and 
FISH. In addition, the REC-1 cell line showed a heterozygous deletion of part of the long arm of chromosome 2, 
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including the MAP2 gene. A FISH screening of the additional MCL cell lines and 27 primary cases failed to detect 
further cases with chromosomal loss affecting the MAP2 gene.  
Mutation analysis of MAP2 was performed in 40 primary MCL and 5 MCL cell lines by DHPLC of the coding 
exons and the exon/intron boundaries followed by sequencing aberrant fragments. The DHPLC screening of the 
MAP2 gene identified a G>A transition in one MCL case (MCL 16). This mutation affected the first position of a 
coding triplet in exon 5 causing an amino acid change from glutamic acid (E) to lysine (K) (Figure 4). There is no 
evidence for a SNP at this DNA sequence position in NCBI Build database and DHPLC analyses failed to detect 
this alteration in 50 DNA samples (100 alleles) derived from peripheral blood of healthy individuals (data not 
shown).  
To investigate the DNA methylation status of the CpG island within the MAP2 promotor (Figure 5A), bisulfite-
treated DNA probes of 5 MCL cell lines and 20 MCL cases were subjected to MSP. In 18 of the 20 MCL cases the 
pattern of PCR products indicated partial DNA hypermethylation, including the MCL 16 with the MAP2 mutation. 
The DNAs of the MCL cell lines JEKO-1 and HBL-2 were also partially hypermethylated and the MSP pattern of 
the REC-1 cell line indicated virtually complete DNA methylation of the MAP2 CpG island (Figure 5B). 
Noteworthy, REC-1 has only one MAP2 allele due to a heterozygous deletion of part of chromosome 2. The MCL 
cell line GRANTA-519 showed only a weak PCR product of methylated DNA and the additional two MCL cases 
and the MCL cell line MAVER-1 seemed to be completely unmethylated. In contrast to the distribution in MCL, 8 
non-tumourous controls (4 tonsils and 4 PB) showed a MSP pattern indicating an unmethylated status of MAP2 
promotor. These findings could be confirmed by bisulfite sequencing (Figure 5C-D, Supplementary Figure 3).   
To investigate how DNA methylation status of the MAP2 CpG island correlates with MAP2 gene expression in 
MCL cell lines we performed real-time RT-PCR. Two different primer assays were used to detect all known MAP2 
transcript variants (Figure 5E). In UPN-1 and REC-1, no expression of MAP2 transcripts could be detected. Real-
time RT-PCR results of HBL-2 indicated reduced expression of all MAP2 transcripts compared to control LN 
tissue. In GRANTA-519 and MAVER-1 the expression of MAP2 transcripts was similar or minimally reduced 
whereas JEKO-1 showed a considerable higher expression of all MAP2 transcripts compared to the LN tissue 
(Figure 5E). Similarly results were obtained using a freshly prepared tonsil as reference (data not shown). 
TP53 gene. Due to its influence on microtubule dynamics, the TP53 gene was subjected to mutation analyses 
in all samples of the MCL GeneChip panel. One case showing a homozygous TP53 mutation was already 
analysed as part of the pUPD investigation. In six of the additional 25 primary cases mutations within the coding 
sequence of TP53 were detected using DHPLC followed by sequencing aberrant fragments. Detected mutations 
include 6 different point mutations and one microdeletion of one single base pair (Table 3). In all these cases copy 
number and LOH analyses of the 100K GeneChip data indicated genomic loss of the second allele 
(Supplementary Table 6). Three point mutations and one microdeletion affecting the coding sequence of TP53 
gene were detected in MCL cell lines UPN-1, HBL-2, MAVER-1 and JEKO-1 (Table 3). In all these cell lines the 
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second TP53 allele was deleted. Both REC-1 and GRANTA-519 exhibited the wild type allele but the latter 
showed a heterozygous deletion of TP53 gene locus. Some of the MCL cell line data has been already reported 




100K GeneChip microarray data 
In the present study, we performed 100K GeneChip microarray analyses of 26 primary MCL and 6 MCL cell 
lines. The use of short synthetic oligonucleotides as arrayed elements allowed the detection of genomic 
imbalances with high resolution (approx. 24kb) and moreover genotyping was performed simultaneously to 
identify regions of pUPD. Overall, the identified genomic imbalance pattern was consistent with those previously 
described by cytogenetics or arrayCGH studies in MCL (de Leeuw, et al 2004, Kohlhammer, et al 2004, Mestre-
Escorihuela, et al 2007, Pinyol, et al 2007, Rubio-Moscardo, et al 2005b, Tagawa, et al 2005). 
Using the GeneChip mapping technique, we not only delineated previously reported alterations but also 
identified novel regions of recurrent genomic imbalance in MCL. Taking advantage of the high resolution of the 
used SNP arrays, we focused on detecting high-level amplifications and small regions of homozygous loss. In this 
way, novel regions harbouring potential oncogenes or candidate TSG were identified, which might be involved in 
tumourigenesis. Moreover, we introduced two useful bioinformatic approaches for identifying homozygous losses 
in 100K GeneChip data and point out advantages and disadvantages.     
In line with a recent study of 5 MCL cell lines (Nielaender, et al 2006), LOH analysis of primary MCL tumor tissue 
demonstrated that pUPD is a recurrent genetic mechanism in MCL tumourigenesis. Genomic distribution of 
detected pUPD in the analysed primary MCL showed that recurrently affected regions such as 11q and 13q are 
commonly targeted by deletions in MCL. Furthermore, we could explicitly demonstrate TSG inactivation by pUPD 
targeting the TP53 gene locus in 17p13.1. A homozygous missense mutation affecting a DNA binding domain 
was detected. This mutation is frequent in lymphomas (28%) and has been reported to be deleterious for TP53-
DNA interaction (http://www-p53.iarc.fr). TP53 gene inactivation by chromosomal deletion is a common 
chromosomal event in MCL and is associated with poor prognosis (Rubio-Moscardo, et al 2005b). In this study, 
we could show that pUPD is an alternative mechanism to chromosomal deletion leading to homozygosity of a 
TSG inactivating mutation. Thus, pUPD seems to be a critical genetic event in MCL pathogenesis.  
Genes encoding microtubule-associated proteins as targets of chromosomal 
aberrations 
Interestingly, analysis of the 100K GeneChip data identified different genes encoding microtubule-associated 
proteins (MAPs) to be involved in chromosomal alterations in MCL. MAPs are cellular proteins that are associated 
with microtubules and alter their dynamics. Microtubule dynamic property is crucial for the assembly of the mitotic 
spindle and the attachment and movement of chromosomes along the spindle (Zhai, et al 1996). Microtubule-
targeting drugs suppressing microtubule dynamics are widely used as cancer chemotherapeutic agents (Jordan 
and Wilson 2004). In addition to their direct involvement in the physical process of mitosis, microtubules also 
serve as scaffolds for signalling molecules (Mollinedo and Gajate 2003). The family of MAPs includes products of 
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oncogenes, tumour suppressors and apoptosis regulators, suggesting that alteration of microtubule dynamics and 
changes in the scaffolding properties of microtubules may be critical events in tumourigenesis and tumour 
progression (Bhat and Setaluri 2007). Until now, alterations in microtubule organisation have not been reported in 
MCL(Jares, et al 2007). 
In this study, a homozygous deletion of the MAP2 locus was identified in the MCL cell line UPN-1. Real time RT-
PCR revealed absence of MAP2 expression in UPN-1 and REC-1. REC-1 harbours a heterozygous deletion of 
part of the long arm of chromosome 2 and epigenetic studies showed complete DNA methylation of the CpG 
island of the remaining MAP2 allele. Moreover, the DNAs of the MCL cell lines JEKO-1 and HBL-2 were also 
partially hypermethylated. MSP analysis demonstrated partial hypermethylation in 90% of 20 investigated primary 
MCL. In one of these cases showing partial hypermethylation, a point mutation affecting the coding sequence of 
MAP2 was identified. These findings suggest that DNA hypermethylation is a frequent mechanism leading to 
MAP2 gene inactivation in MCL. MAP2 protein participates in the stabilisation of microtubules and is 
predominantly expressed in neurons, where it is essential for the regulation of organelle transport within axon and 
dendrites (Sanchez, et al 2000). Moreover, MAP2 was the first protein shown to copurify and interact directly with 
the regulatory subunit of the protein kinase A (PKA), also known as cAMP-dependent protein kinase (cAPK) 
(Theurkauf and Vallee 1982, Vallee, et al 1981). Among other cellular effects, PKA-catalysed phosphorylation 
modulates cell growth, cell division and actin cytoskeleton rearrangements. MAP2 protein operates as a A-kinase 
anchoring protein (AKAP) and targets the PKA to microtubules. Attachment to microtubules occurs through its 
tubulin-binding domain (Hirokawa 1994, Serrano, et al 1984). MAP2 also harbours a conserved binding site for 
phosphatase PP2A, although direct binding of the phosphatase has yet to be reported. PP2A represents a family 
of heterotrimeric serine/threonine phosphatases implicated in the regulation of a plethora of cellular processes 
such as apoptosis, transcription, translation, DNA replication, signal transduction, protection against 
tumourigenesis and cell division (Janssens, et al 2005). In 2005, Soltani et al. reported that MAP2 expression is 
associated with prognosis in melanoma. A five-year clinical follow-up study showed longer disease-free survival of 
patients whose primary tumors express abundant MAP2 as compared with patients with weak or no MAP2 
expression. Moreover, exogenous expression by adenovirus leads to cell cycle arrest, growth inhibition and 
apoptosis in metastatic melanoma cells (Fang, et al 2001, Soltani, et al 2005). Thus, lack of MAP2 expression 
might be also associated with MCL pathogenesis.  
The p53 protein is also associated with microtubules in vitro and in vivo (Giannakakou, et al 2000) and has been 
reported to regulate other microtubule-associated proteins (Johnsen, et al 2000, Mirza, et al 2002, Murphy, et al 
1999). TP53 gene inactivation by chromosomal deletions or by mutations is a common genetic alteration in MCL. 
In 2003, Galmarini et al. (Galmarini, et al 2003) demonstrated that microtubule protein composition was altered in 
TP53 mutants (mut-p53) and dynamic instability of microtubules was significantly increased. Mutation analyses in 
this report identified 7 primary MCL cases to harbour homozygous mutations in the coding sequence of TP53. In 
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all these cases, the second allele got lost by chromosomal deletion or pUPD. Similarly, TP53 was shown to be 
homozygously mutated in 4 of 6 investigated MCL cell lines (Amin, et al 2003, Camps, et al 2006, M'Kacher, et al 
2003, Zamo, et al 2006). Galmarini et al. (Galmarini, et al 2003) also reported that the MAP6 (also called STOP) 
protein and its corresponding mRNA-expression were increased in the mut-p53 cells, than in the wt-p53 cells 
suggesting negative transcriptional regulation of MAP6 by p53 protein. Interestingly, our MCL GeneChip data 
showed high-level amplification of MAP6 in the three MCL cell lines MAVER-1, JEKO-1 and HBL-2. Real-time RT-
PCR detected higher expression of MAP6 in JEKO-1, GRANTA-519 and REC-1 compared with non-tumourous 
tonsil tissue. The apparent lack of correlation between MAP6 gene dosage and expression in MAVER-1 and 
HBL-2 might be caused by putative non-neuronal transcripts variants that cannot be detected with the primers 
used. According to this, the murine homologue shows non-neuronal transcript variants, which lacks whole exons 
(Bosc, et al 2003). So far, no human non-neuronal transcript variant has been identified. High-level amplification 
of MAP6 was frequently detected in MCL cell lines but in none of the investigated primary MCL. As cell lines are 
frequently derived from cases with advanced disease, this findings might indicate that MAP6 amplification is 
associated with disease progression. In line with this hypothesis, a chromosomal rearrangement of another MAP 
gene, i.e. MAP4, was recently identified as secondary alteration in a large B-cell lymphoma (DLBCL), which was 
present at relapse but not at initial diagnosis (Murga Penas, et al 2006). According to our GeneChip data, it is 
widely assumed that cell lines generally harbour an increased number of chromosomal aberrations compared to 
the primary tumour cells. 
Our study provides evidence that alterations of microtubule dynamics might be critical in MCL tumourigenesis and 
tumour progression. Nineteen of the 26 primary MCL from the SNP array panel and 5 of the 6 MCL cell lines 
harboured a genetic or epigenetic defect in at least 1 of the 3 microtubule-associated genes MAP2, MAP6 and 
TP53. 6 primary cases were not analysed by methylation-specific methods. Only 1 case and 1 MCL cell line, in 
which all 3 gene loci were analysed, did not show any of the investigated alterations. 
The complexity of the mitotic spindle requires fine tuning of the dynamics of all microtubules for proper function. 
MAPs can either stabilise or destabilise microtubules. Changes in levels of expression have been reported to 
correlate with aggressiveness of cancer cells or their sensitivity to microtubule-targeting agents. Although plenty 
of studies exist about microtubule associated proteins in neurons, where they play a critical role in neurite 
outgrowth and dendrite development, their mechanisms of operation in mitotic spindle regulation are rather 
unclear. Mitotic spindle organisation is a fine tuning process and investigation of the involved proteins is difficult 
due to low dosage. In contrast to abundant gene expression in brain tissue, expression of MAP2 and MAP6 is 
hardly detectable in other kinds of tissues. In our study, genomic alterations, such as MAP6 amplification or MAP2 
and TP53 inactivation, provide evidence for the involvement of microtubule-associated genes in MCL 
tumourigenesis. Alterations in microtubule dynamics and mitotic spindle organisation might contribute to the 
karyotype complexity and chromosomal instability which are characteristic features of MCL. Supporting this 
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hypothesis, a recent study underlined the high expression level of centrosome-associated gene products in 
blastoid MCL (Neben, et al 2007). MCL has one of the worst prognoses among all lymphomas. There is no 
therapy that can be considered as standard. Resistance against microtubule-targeting chemotherapeutic agents 
may be the consequence of changes in microtubule dynamics. 
In conclusion, our study demonstrates that 100K GeneChip microarray analyses is a useful strategy to analyse 
MCL genomes with regard to genomic imbalances, particularly homozygous deletions, as well as pUPD. 
Moreover, we identified novel candidate TSG and oncogene loci which might harbour genes involved in MCL 
pathogenesis. Interestingly, different genes encoding microtubule-associated proteins could be identified as 
targets of chromosomal aberrations in MCL. Our findings suggest that alteration of microtubule dynamics is a 
critical genetic event in MCL. 
References 
 
(2006) Affymetrix (2006) BRLMM: an improved genotype calling method for the genechip human mapping 500k 
array set. Tech. rep., Affymetrix, Inc. White Paper. 
Amin, H.M., McDonnell, T.J., Medeiros, L.J., Rassidakis, G.Z., Leventaki, V., O'Connor, S.L., Keating, M.J. & Lai, R. 
(2003) Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med, 127, 424-431. 
Arnold, N., Gross, E., Schwarz-Boeger, U., Pfisterer, J., Jonat, W. & Kiechle, M. (1999) A highly sensitive, fast, 
and economical technique for mutation analysis in hereditary breast and ovarian cancers. Hum Mutat, 
14, 333-339. 
Bea, S., Tort, F., Pinyol, M., Puig, X., Hernandez, L., Hernandez, S., Fernandez, P.L., van Lohuizen, M., Colomer, 
D. & Campo, E. (2001) BMI-1 gene amplification and overexpression in hematological malignancies 
occur mainly in mantle cell lymphomas. Cancer Res, 61, 2409-2412. 
Beroukhim, R., Lin, M., Park, Y., Hao, K., Zhao, X., Garraway, L.A., Fox, E.A., Hochberg, E.P., Mellinghoff, I.K., 
Hofer, M.D., Descazeaud, A., Rubin, M.A., Meyerson, M., Wong, W.H., Sellers, W.R. & Li, C. (2006) 
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. 
PLoS Comput Biol, 2, e41. 
Bhat, K.M. & Setaluri, V. (2007) Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer 
Res, 13, 2849-2854. 
Bignell, G.R., Huang, J., Greshock, J., Watt, S., Butler, A., West, S., Grigorova, M., Jones, K.W., Wei, W., Stratton, 
M.R., Futreal, P.A., Weber, B., Shapero, M.H. & Wooster, R. (2004) High-resolution analysis of DNA 
copy number using oligonucleotide microarrays. Genome Res, 14, 287-295. 
Bosc, C., Andrieux, A. & Job, D. (2003) STOP proteins. Biochemistry, 42, 12125-12132. 
Bruce, S., Leinonen, R., Lindgren, C.M., Kivinen, K., Dahlman-Wright, K., Lipsanen-Nyman, M., Hannula-Jouppi, 
K. & Kere, J. (2005) Global analysis of uniparental disomy using high density genotyping arrays. J Med 
Genet, 42, 847-851. 
Camps, J., Salaverria, I., Garcia, M.J., Prat, E., Bea, S., Pole, J.C., Hernandez, L., Del Rey, J., Cigudosa, J.C., 
Bernues, M., Caldas, C., Colomer, D., Miro, R. & Campo, E. (2006) Genomic imbalances and patterns of 
karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res, 30, 923-934. 
de Leeuw, R.J., Davies, J.J., Rosenwald, A., Bebb, G., Gascoyne, R.D., Dyer, M.J., Staudt, L.M., Martinez-Climent, 
J.A. & Lam, W.L. (2004) Comprehensive whole genome array CGH profiling of mantle cell lymphoma 
model genomes. Hum Mol Genet, 13, 1827-1837. 
Fang, D., Hallman, J., Sangha, N., Kute, T.E., Hammarback, J.A., White, W.L. & Setaluri, V. (2001) Expression of 
microtubule-associated protein 2 in benign and malignant melanocytes: implications for 
differentiation and progression of cutaneous melanoma. Am J Pathol, 158, 2107-2115. 
Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., Molloy, P.L. & Paul, C.L. (1992) A 
genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual 
DNA strands. Proc Natl Acad Sci U S A, 89, 1827-1831. 
16 
 
Galmarini, C.M., Kamath, K., Vanier-Viornery, A., Hervieu, V., Peiller, E., Falette, N., Puisieux, A., Ann Jordan, M. 
& Dumontet, C. (2003) Drug resistance associated with loss of p53 involves extensive alterations in 
microtubule composition and dynamics. Br J Cancer, 88, 1793-1799. 
Giannakakou, P., Sackett, D.L., Ward, Y., Webster, K.R., Blagosklonny, M.V. & Fojo, T. (2000) p53 is associated 
with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol, 2, 709-717. 
Gladden, A.B., Woolery, R., Aggarwal, P., Wasik, M.A. & Diehl, J.A. (2006) Expression of constitutively nuclear 
cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene, 25, 998-1007. 
Gross, E., Kiechle, M. & Arnold, N. (2001) Mutation analysis of p53 in ovarian tumors by DHPLC. J Biochem 
Biophys Methods, 47, 73-81. 
Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D. & Baylin, S.B. (1996) Methylation-specific PCR: a novel PCR 
assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 93, 9821-9826. 
Hirokawa, N. (1994) Microtubule organization and dynamics dependent on microtubule-associated proteins. 
Curr Opin Cell Biol, 6, 74-81. 
Janssens, V., Goris, J. & Van Hoof, C. (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev, 15, 34-
41. 
Jares, P., Colomer, D. & Campo, E. (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: 
perspectives for new targeted therapeutics. Nat Rev Cancer, 7, 750-762. 
Johnsen, J.I., Aurelio, O.N., Kwaja, Z., Jorgensen, G.E., Pellegata, N.S., Plattner, R., Stanbridge, E.J. & Cajot, J.F. 
(2000) p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-
cycle arrest. Int J Cancer, 88, 685-691. 
Jordan, M.A. & Wilson, L. (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer, 4, 253-265. 
Kohlhammer, H., Schwaenen, C., Wessendorf, S., Holzmann, K., Kestler, H.A., Kienle, D., Barth, T.F., Moller, P., 
Ott, G., Kalla, J., Radlwimmer, B., Pscherer, A., Stilgenbauer, S., Dohner, H., Lichter, P. & Bentz, M. 
(2004) Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high 
frequency of aberrations and allows a refined characterization of consensus regions. Blood, 104, 795-
801. 
Lin, M., Wei, L.J., Sellers, W.R., Lieberfarb, M., Wong, W.H. & Li, C. (2004) dChipSNP: significance curve and 
clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics, 20, 1233-1240. 
Lovec, H., Grzeschiczek, A., Kowalski, M.B. & Moroy, T. (1994) Cyclin D1/bcl-1 cooperates with myc genes in the 
generation of B-cell lymphoma in transgenic mice. EMBO J, 13, 3487-3495. 
M'Kacher, R., Bennaceur, A., Farace, F., Lauge, A., Plassa, L.F., Wittmer, E., Dossou, J., Violot, D., Deutsch, E., 
Bourhis, J., Stoppa-Lyonnet, D., Ribrag, V., Carde, P., Parmentier, C., Bernheim, A. & Turhan, A.G. 
(2003) Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. 
Oncogene, 22, 7905-7912. 
Martin-Subero, J.I., Harder, L., Gesk, S., Schlegelberger, B., Grote, W., Martinez-Climent, J.A., Dyer, M.J., Novo, 
F.J., Calasanz, M.J. & Siebert, R. (2002) Interphase FISH assays for the detection of translocations with 
breakpoints in immunoglobulin light chain loci. Int J Cancer, 98, 470-474. 
Mestre-Escorihuela, C., Rubio-Moscardo, F., Richter, J.A., Siebert, R., Climent, J., Fresquet, V., Beltran, E., Agirre, 
X., Marugan, I., Marin, M., Rosenwald, A., Sugimoto, K.J., Wheat, L.M., Karran, E.L., Garcia, J.F., 
Sanchez, L., Prosper, F., Staudt, L.M., Pinkel, D., Dyer, M.J. & Martinez-Climent, J.A. (2007) 
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood, 109, 271-
280. 
Mirza, A., McGuirk, M., Hockenberry, T.N., Wu, Q., Ashar, H., Black, S., Wen, S.F., Wang, L., Kirschmeier, P., 
Bishop, W.R., Nielsen, L.L., Pickett, C.B. & Liu, S. (2002) Human survivin is negatively regulated by wild-
type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 21, 2613-2622. 
Mollinedo, F. & Gajate, C. (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis, 8, 
413-450. 
Murga Penas, E.M., Kawadler, H., Siebert, R., Frank, M., Ye, H., Hinz, K., Becher, C., Hummel, M., Barth, T.F., 
Bokemeyer, C., Stein, H., Trumper, L., Moller, P., Marynen, P., Du, M.Q., Yang, X., Hansmann, M.L. & 
Dierlamm, J. (2006) A novel fusion of the MALT1 gene and the microtubule-associated protein 4 
(MAP4) gene occurs in diffuse large B-cell lymphoma. Genes Chromosomes Cancer, 45, 863-873. 
Murphy, M., Ahn, J., Walker, K.K., Hoffman, W.H., Evans, R.M., Levine, A.J. & George, D.L. (1999) Transcriptional 
repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes 
Dev, 13, 2490-2501. 
Nannya, Y., Sanada, M., Nakazaki, K., Hosoya, N., Wang, L., Hangaishi, A., Kurokawa, M., Chiba, S., Bailey, D.K., 
Kennedy, G.C. & Ogawa, S. (2005) A robust algorithm for copy number detection using high-density 
oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res, 65, 6071-6079. 
17 
 
Neben, K., Ott, G., Schweizer, S., Kalla, J., Tews, B., Katzenberger, T., Hahn, M., Rosenwald, A., Ho, A.D., Muller-
Hermelink, H.K., Lichter, P. & Kramer, A. (2007) Expression of centrosome-associated gene products is 
linked to tetraploidization in mantle cell lymphoma. Int J Cancer, 120, 1669-1677. 
Nielaender, I., Martin-Subero, J.I., Wagner, F., Martinez-Climent, J.A. & Siebert, R. (2006) Partial uniparental 
disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma. 
Leukemia, 20, 904-905. 
Nielander, I., Bug, S., Richter, J., Giefing, M., Martin-Subero, J.I. & Siebert, R. (2007) Combining array-based 
approaches for the identification of candidate tumor suppressor loci in mature lymphoid neoplasms. 
APMIS, 115, 1107-1134. 
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P. & Olivier, M. (2007) Impact of mutant 
p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent 
developments in the IARC TP53 database. Hum Mutat, 28, 622-629. 
Pinyol, M., Bea, S., Pla, L., Ribrag, V., Bosq, J., Rosenwald, A., Campo, E. & Jares, P. (2007) Inactivation of RB1 in 
mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and 
microarray analysis. Blood, 109, 5422-5429. 
Rubio-Moscardo, F., Blesa, D., Mestre, C., Siebert, R., Balasas, T., Benito, A., Rosenwald, A., Climent, J., 
Martinez, J.I., Schilhabel, M., Karran, E.L., Gesk, S., Esteller, M., deLeeuw, R., Staudt, L.M., Fernandez-
Luna, J.L., Pinkel, D., Dyer, M.J. & Martinez-Climent, J.A. (2005a) Characterization of 8p21.3 
chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent 
tumor suppressor genes. Blood, 106, 3214-3222. 
Rubio-Moscardo, F., Climent, J., Siebert, R., Piris, M.A., Martin-Subero, J.I., Nielander, I., Garcia-Conde, J., Dyer, 
M.J., Terol, M.J., Pinkel, D. & Martinez-Climent, J.A. (2005b) Mantle-cell lymphoma genotypes 
identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient 
outcome. Blood, 105, 4445-4454. 
Sanchez, C., Diaz-Nido, J. & Avila, J. (2000) Phosphorylation of microtubule-associated protein 2 (MAP2) and its 
relevance for the regulation of the neuronal cytoskeleton function. Prog Neurobiol, 61, 133-168. 
Serrano, L., Avila, J. & Maccioni, R.B. (1984) Controlled proteolysis of tubulin by subtilisin: localization of the 
site for MAP2 interaction. Biochemistry, 23, 4675-4681. 
Soltani, M.H., Pichardo, R., Song, Z., Sangha, N., Camacho, F., Satyamoorthy, K., Sangueza, O.P. & Setaluri, V. 
(2005) Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, 
inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am J 
Pathol, 166, 1841-1850. 
Tagawa, H., Karnan, S., Suzuki, R., Matsuo, K., Zhang, X., Ota, A., Morishima, Y., Nakamura, S. & Seto, M. (2005) 
Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of 
the proapoptotic gene BIM. Oncogene, 24, 1348-1358. 
Theurkauf, W.E. & Vallee, R.B. (1982) Molecular characterization of the cAMP-dependent protein kinase bound 
to microtubule-associated protein 2. J Biol Chem, 257, 3284-3290. 
Vallee, R.B., DiBartolomeis, M.J. & Theurkauf, W.E. (1981) A protein kinase bound to the projection portion of 
MAP 2 (microtubule-associated protein 2). J Cell Biol, 90, 568-576. 
Williams, M.E., Swerdlow, S.H., Rosenberg, C.L. & Arnold, A. (1992) Characterization of chromosome 11 
translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res, 52, 5541s-
5544s. 
Zamo, A., Ott, G., Katzenberger, T., Adam, P., Parolini, C., Scarpa, A., Lestani, M., Menestrina, F. & Chilosi, M. 
(2006) Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell 
lymphoma. Haematologica, 91, 40-47. 
Zhai, Y., Kronebusch, P.J., Simon, P.M. & Borisy, G.G. (1996) Microtubule dynamics at the G2/M transition: 
abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for 
spindle morphogenesis. J Cell Biol, 135, 201-214. 
Zhao, X., Li, C., Paez, J.G., Chin, K., Janne, P.A., Chen, T.H., Girard, L., Minna, J., Christiani, D., Leo, C., Gray, J.W., 
Sellers, W.R. & Meyerson, M. (2004) An integrated view of copy number and allelic alterations in the 




Table 1: Homozygous deletions in MCL cell lines 














liberal  screening 
[start-stop in bp1] 
sensitive screening 










1p32.3 not detected 50 837 181-57 453 350 
(Mestre-Escorihuela, et al 
2007) 
not done UPN-1 CDKN2C/P18 
2q13 111 616 112-112 182 931 111 616 112-112 155 057 (Tagawa, et al 2005) not done JEKO-1 BIM 
2q34 210 048 358-210 472 004 210 048 358-210 472 004 210 079 601-210 462 202 confirmed UPN-1 MAP2 
2q37.3 not detected 237 396 643-237 486 004 237 272 264-237 637 712 confirmed UPN-1 no genes 
9p21.3 21 948 524-22 102 599 21 948 524-22 090 176 
(de Leeuw, et al 2004, 
Kohlhammer, et al 2004, 










9p21.1 28 761 537-30 316 115 28 761 537-30 316 115 
confirmed but not 
delineated by PCR 
not done MAVER-1 no genes 
12p13.1 not detected 13 617 759-13 618 078 13 616 272-13 652 667 not done REC-1 GRIN2B 
13q14.2 not detected 47 812 793-47 817 924 (Pinyol, et al 2007) not done UPN-1 RB1 
13q33.1 101 552 480-101 943 751 101 552 480-101 943 751 
confirmed by FISH  not 
delineated by PCR  
confirmed JEKO-1 FGF14 
18q22.1 62 853 023-63 491 358 63 097 606-63 491 358 62 390 461-64 346 179 confirmed UPN-1 c18orf4 




Xp22.31 not detected 6 492 343-6 543 186 CNV2 not done JEKO-1 no genes 
Xq28 not detected 153 981 072 CNV2 not done GRANTA-519 no genes 
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Table 2: Putative and confirmed homozygous deletions in MCL primary cases 
locus1 
sensitive screening 
 [start-stop in bp1] 
liberal screening 
[start-stop in bp1] 
number of 
affected MCL 
FISH confirmation candidate genes 
1p21.2 100 823 226-100 823 636 not detected 1 not done (<100kb) no genes 
3p26.3 1 510 440-1 511 278 not detected 1 not done (CNV2) no genes 
4q22.1 90 356 219-90 356 586 not detected 1 not done (CNV2) no genes 
5q22.2 111 710 742-111 711 216 not detected 1 not done (CNV2) EPB41L4A 
9p24.1 7 501 166-7 503 589 not detected 1 not done (CNV2) no genes 
9p23 12 742 340-12 750 718 8 916 956-12 974 756 1 not done (CNV2) PTPRD, TYRP1 





9p21.2 27 692 974-27 693 855 not detected 1 not done (<100kb) no genes 
9p21.1 not detected 30 425 441-31 302 460 1 not done (CNV2) no genes 
11q22.1 100 654 097-100 773 657 
100 546 098-102 615 
349 
1 
no assay applicable due to 
repetitive sequences 
BIRC2, BIRC3 
11q22.3 109 749 455-109 749 570 not detected 1 not done (CNV2) TMED 
12p13.1 13 617 759-13 618 078 not detected 1 not done (<100kb) GRIN2B 
22q11.22 21 099 653-21 337 561 21 099 653-21 479 136 1 not done (CNV2) IGL 




Xp21.2 29 303 376-29 351 134 not detected 1 not done (CNV2) IL1RAPL1 
Xp21.1 33 396 094-33 415 950 not detected 1 not done (CNV2) no genes 
Xq21.33 98 159 771-98 164 282 not detected 2 not done (<100kb) no genes 






Table 3: TP53 mutation analyses in MCL 
MCL primary cases TP53 mutation second abberation in 17p13.1 
MCL 4 g.12178 delC - p.122X deletion 
MCL 6 g.14487 G > T - p.R273L deletion 
MCL 8 g.14490 T > A - p.V274D pUPD 
MCL 15 g.13203 G > A - p.R175H deletion 
MCL 17 g.14070 C > T - p.R248L deletion 
MCL 19 g.12108 G > T - p.E62X deletion 
MCL 21 g.13091 G > C - p.A138P deletion 
MCL cell lines TP53 mutation second abberation in 17p13.1 
UPN-1 g.14525 G>A - p.E286K deletion 
MAVER-1 g.14511 A>G - p.D281G deletion 
JEKO-1 g.12096 delC - p.58X deletion 
HBL-2 g.14511 A>G - p.D281G deletion 
g.: genomic sequence position, p.: protein sequence position (http://www-p53.iarc.fr)
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Titles and legends to figures 
Figure 1: Genome-wide detection of copy number changes in MCL primary cases. Proportion of gains and 
losses analysing GeneChip data of 26 MCL primary cases are displayed from 1pter to Xqter. Green columns 
indicate chromosomal gain, whereas red columns indicate loss of genetic material.    
Figure 2: Partial uniparental disomy (pUPD) in MCL. A) Genome-wide distribution of pUPD in 26 primary MCL 
cases detected by 100K GeneChip Mapping (Affymetrix). Proportion of MCL cases showing pUPD is displayed in 
turquoise. Chromosomes are shown from 1pter (left) to Xqter (right). B) Detection of pUPD in the short arm of 
chromosome 17 in MCL 8. The profile of genomic imbalances is given as black dots with a value of 2 indicating a 
balanced status. Chromosome 17 is shown from pter (left) to qter (right). Heterozygous calls are given as green 
dots and the estimated LOH region is overlaid in grey. A blue arrow indicates chromosomal location of the TP53 
gene. C) FISH analysis using a locus-specific probe consisting of BAC clones labelled in spectrum orange (TP53) 
and spectrum green (control locus in 17q21.2). Signal constellation indicates a normal gene dosage of two copies 
in the MCL 8. D) Homozygous point mutation affecting exon 8 of TP53 in the same MCL which shows pUPD in 
17p13.1. 
Figure 3: High level amplification in 11q13.5. A) Genomic profiles of part of chromosome 11 in 3 MCL cell 
lines. Copy number is given as black dots with a value of 2 indicating a balanced status. Chromosomal region in 
the long arm is shown from centromeric to telomeric. The minimal altered region is indicated by blue vertical bars. 
B-D) Interphase FISH of the MCL cell lines using a locus-specific probe for the MAP6 gene (spectrum green) and 
a control locus in 11q22.3 (spectrum orange). E-F) R banding followed by FISH on metaphases of MAVER-1 
using the described MAP6 probe. High level amplification was shown to affect two derivative chromosomes 6  
[a:der(6)(6pter?6q22::11q13?::11q22?11q23::11q22->11q23::?),b:der(6)(?::6p21?6q22::11q13?11q14::11q23? 
amp)].  
Figure 4: Homozygous deletion in 2q34. A) Genomic profile of part of the chromosome 2 in the MCL cell line 
UPN-1. Copy number is given as black dots with a value of 2 indicating a balanced status. Chromosomal region in 
the long arm is shown from centromeric to telomeric. A red arrow indicates the homozygously deleted region. A 
Genome Browser extract (NCBI Build 35) displays gene content and the chromosomal position of primers (red 
bars) for delineation of the minimal affected region. B) Multiplex-PCR of the target gene and a control locus 
confirmed the homozygous deletion of MAP2 gene but not of the adjacent coding sequences of RNAz s59616 
and C2orf21. C) DHPLC chromatograms of the primary MCL 16 (red) and a healthy control (blue). D) Sequencing 
of the aberrant fragment revealed a heterozygous mutation in exon 5 of MAP2 changing amino acid composition 
of the protein (E163K). Here, the reverse strand is displayed showing a C>T transition.  
Figure 5: Epigenetic and expression studies of MAP2. A) Genome Browser extract (NCBI Build 35) displaying 
location of MAP2 CPG island. B) Methylation specific PCR (MSP) of REC-1, two primary MCL and controls. 
Methylation specific amplification was verified using universal methylated (MC) and universal unmethylated (UC) 
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DNA as controls. Genomic DNA (gC) was tested to exclude unspecific amplification. C) Part of the analysed 
MAP2 CpG island sequences investigating bisulfite-treated DNA of REC-1 and a tonsil. The included CpG 
dinucleotides 5-11 are marked by black bars. D) Bisulfite genomic sequencing of the MAP2 CpG island in the 
MCL cell line REC-1 and two primary MCL. A tonsil and peripheral blood of healthy donors were used as controls. 
Every column represents a CpG dinucleotide and every row represents one of 10 sequenced clones. Black and 
white spots indicate methylated and unmethylated CpGs, respectively. Grey spots indicate CpG dinucleotides 
which failed to be analysed. E) Real-time Reverse Transcription (RT-) PCR. Two primer assays were applied to 
investigate all known MAP2 transcripts. Primer position is displayed by black arrows. Expression of MAP2 
transcripts was examined in 6 MCL cell lines and compared to MAP2 expression in lymph node tissue of healthy 
individuals. Each value has been normalised to the average expression of three housekeeping genes. In UPN-1 
and REC-1 no MAP2 expression was detected, thus log2 ratio was not calculable (N/C).  
 
 
